Supriya Lifescience Limited (BOM:543434)
India · Delayed Price · Currency is INR 952.15
+50.40 (5.59%)
At close: Jun 4, 2026
Supriya Lifescience Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Supriya Lifescience stock has a consensus rating of "Buy" and an average price target of ₹940.00. The average 1-year stock price forecast is 1.28% lower than the current stock price, while the lowest is ₹850.00 (-10.73%) and the highest is ₹1,030 (+8.18%).
Price Target: ₹940.00 (-1.28%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Supriya Lifescience stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Nov '25 | Jan '26 | Feb '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 1 | 1 | 1 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 | 2 |
Financial Forecast
Revenue This Year
9.94B
from 8.28B
Increased by 20.01%
Revenue Next Year
12.42B
from 9.94B
Increased by 24.99%
EPS This Year
30.50
from 26.02
Increased by 17.20%
EPS Next Year
39.80
from 30.50
Increased by 30.49%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 9.9B | ||
| Avg | 9.9B | ||
| Low | 9.9B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 20.0% | ||
| Avg | 20.0% | ||
| Low | 20.0% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | 30.50 | ||
| Low | - |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | 17.2% | ||
| Low | - |